Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19797113 | 0.94 | SPHK1 (0.37) | SPHK1TSHRCYP2C9CA1CA2 | |
| SCHEMBL19796931 | 0.93 | SPHK1 (0.35) | ACE2SPHK1TSHRCA1CA2 | |
| SCHEMBL19796810 | 0.92 | SPHK1 (0.37) | ACE2SPHK1TSHRCYP2C9CA1 | |
| SCHEMBL19796827 | 0.89 | P2RY14 (0.33) | ACE2SPHK1TSHRCYP2C9CA1 | |
| SCHEMBL19797085 | 0.88 | SPHK1 (0.38) | SPHK1TSHRCYP2C9 | |
| SCHEMBL19797111 | 0.88 | SPHK1 (0.38) | SPHK1TSHRCYP2C9 | |
| SCHEMBL19796801 | 0.87 | SPHK1 (0.35) | ACE2SPHK1TSHRCYP2C9RAB9A | |
| SCHEMBL19007871 | 0.87 | CA1 (0.35) | SPHK1TSHRCYP2C9CA1CA2 | |
| SCHEMBL19804621 | 0.87 | FFAR4 (0.38) | CYP2C9CA1CA2PPARG | |
| SCHEMBL19796609 | 0.86 | CNR2 (0.38) | TSHRCYP2C9CA1CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689576-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10385269-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| US-20180208849-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208849-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-26 | — | — | US | disclosed |
| EP-3327101-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20170174993-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174993-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | ACE2 3434/4885SPHK1 608/4885TSHR 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.